ERRb splice variants differentially regulate cell cycle progression http://www.tandfonline.com/doi/pdf/10.4161/15384101.2014.972886

Cell Cycle

Volumn 14, Issue 1, 2015, Pages 31-45

  Heckler, Mary Mazzotta ^a   Riggins, Rebecca B ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Alternative splicing; Cell cycle; ERRbeta; ESRRB; Nuclear receptor; P53; Senescence

Indexed keywords

ESTROGEN RELATED RECEPTOR BETA; PROTEIN P53; STEROID RECEPTOR; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ESRRB PROTEIN, HUMAN; ESTROGEN RECEPTOR; HYDRAZONE DERIVATIVE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL AGING; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PROTEIN DEPLETION; SENESCENCE; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; GENETICS; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; RNA INTERFERENCE; RNA SPLICING; TUMOR CELL LINE;

APOPTOSIS; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; HYDRAZONES; M PHASE CELL CYCLE CHECKPOINTS; RECEPTORS, ESTROGEN; RNA INTERFERENCE; RNA SPLICING; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84921840093     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.972886     Document Type: Article

References (51)

1. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40:1413-5; PMID:18978789; http://dx.doi.org/10.1038/ng.259
2. Kornblihtt AR, Schor IE, Alló M, Dujardin G, Petrillo E, Muñoz MJ. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 2013; 14:153-65; PMID:23385723; http://dx.doi.org/10.1038/nrm3525
3. Busslinger M, Moschonas N, Flavell RA. Beta C thalassemia: aberrant splicing results from a single point mutation in an intron. Cell 1981; 27:289-98; PMID:6895866; http://dx.doi.org/10.1016/0092-8674(81)90412-8
4. Spritz RA, Jagadeeswaran P, Choudary PV, Biro PA, Elder JT, deRiel JK, Manley JL, Gefter ML, Forget BG, Weissman SM. Base substitution in an intervening sequence of a betaC-thalassemic human globin gene. Proc Natl Acad Sci U S A 1981; 78:2455-9; PMID:6264477; http://dx.doi.org/10.1073/pnas.78.4.2455
5. Helmken C, Hofmann Y, Schoenen F, Oprea G, Raschke H, Rudnik-Schöneborn S, Zerres K, Wirth B. Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum Genet 2003; 114:11-21; PMID:14520560; http://dx.doi.org/10.1007/s00439-003-1025-2
6. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993; 363:640-4; PMID:8510758; http://dx.doi.org/10.1038/363640a0
7. Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest 1993; 92:2419-26; PMID:8227358; http://dx.doi.org/10.1172/JCI116848
8. Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bakács A, Coppola L, Karni R. Splicing factor hnRNP A2B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 2011; 71:4464-72; PMID:21586613; http://dx.doi.org/10.1158/0008-5472.CAN-10-4410
9. Choi EJ, Jang YJ, Cha EY, Shin JG, Lee SS. Identification and characterization of novel alternative splice variants of human constitutive androstane receptor in liver samples of Koreans and Caucasians. Drug Metab Dispos 2013; 41:888-96; PMID:23378627; http://dx.doi.org/10.1124/dmd.112.049791
10. Matic M, Corradin AP, Tsoli M, Clarke SJ, Polly P, Robertson GR. The alternatively spliced murine pregnane X receptor isoform, mPXR(delta171-211) exhibits a repressive action. Int J Biochem Cell Biol 2010; 42:672-82; PMID:20060928; http://dx.doi.org/10.1016/j.biocel.2010.01.001
11. Thomas-Chollier M, Watson LC, Cooper SB, Pufall MA, Liu JS, Borzym K, Vingron M, Yamamoto KR, Meijsing SH. A naturally occurring insertion of a single amino acid rewires transcriptional regulation by glucocorticoid receptor isoforms. Proc Natl Acad Sci U S A 2013; 110:17826-31; PMID:24127590; http://dx.doi.org/10.1073/pnas.1316235110
12. Benoit G, Cooney A, Giguere V, Ingraham H, Lazar M, Muscat G, Perlmann T, Renaud JP, Schwabe J, Sladek F, et al. International union of pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev 2006; 58:798-836; PMID:17132856; http://dx.doi.org/10.1124/pr.58.4.10
13. Eichner LJ, Giguére V. Estrogen related receptors (ERRs): a new dawn in transcriptional control of mitochondrial gene networks. Mitochondrion 2011; 11:544-52; PMID:21497207; http://dx.doi.org/10.1016/j.mito.2011.03.121
14. Mitsunaga K, Araki K, Mizusaki H, Morohashi K, Haruna K, Nakagata N, Giguére V, Yamamura K, Abe K. Loss of PGC-specific expression of the orphan nuclear receptor ERR-beta results in reduction of germ cell number in mouse embryos. Mech Dev 2004; 121:237-46; PMID:15003627; http://dx.doi.org/10.1016/j.mod.2004.01.006
15. Luo J, Sladek R, Bader JA, Matthyssen A, Rossant J, Giguére V. Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta. Nature 1997; 388:778-82; PMID:9285590; http://dx.doi.org/10.1038/42022
16. Byerly MS, Al Salayta M, Swanson RD, Kwon K, Peterson JM, Wei Z, Aja S, Moran TH, Blackshaw S, Wong GW. Estrogen-related receptor b deletion modulates whole-body energy balance via estrogen-related receptor g and attenuates neuropeptide Y gene expression. Eur J Neurosci 2013; 37:1033-47; PMID:23360481
17. Byerly MS, Swanson RD, Wong GW, Blackshaw S. Estrogen-related receptor b deficiency alters body composition and response to restraint stress. BMC Physiol 2013; 13:10; PMID:24053666; http://dx.doi.org/10.1186/1472-6793-13-10
18. Collin RW, Kalay E, Tariq M, Peters T, van der Zwaag B, Venselaar H, Oostrik J, Lee K, Ahmed ZM, Caylan R, et al. Mutations of ESRRB encoding estrogenrelated receptor beta cause autosomal-recessive nonsyndromic hearing impairment DFNB35. Am J Hum Genet 2008; 82:125-38; PMID:18179891; http://dx.doi.org/10.1016/j.ajhg.2007.09.008
19. Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E, Lubahn DB. Identification and characterization of two novel splicing isoforms of human estrogen-related receptor beta. J Clin Endocrinol Metab 2006; 91:569-79; PMID:16332939; http://dx.doi.org/10.1210/jc.2004-1957
20. Bombail V, Collins F, Brown P, Saunders PT. Modulation of ER alpha transcriptional activity by the orphan nuclear receptor ERR beta and evidence for differential effects of long- and short-form splice variants. Mol Cell Endocrinol 2010; 314:53-61; PMID:19755138; http://dx.doi.org/10.1016/j.mce.2009.09.007
21. Sengupta D, Bhargava DK, Dixit A, Sahoo BS, Biswas S, Biswas G, Mishra SK. ERRb signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells. Br J Cancer 2014; 110:2144-58; PMID:24667650; http://dx.doi.org/10.1038/bjc.2014.53
22. Yu S, Wong YC, Wang XH, Ling MT, Ng CF, Chen S, Chan FL. Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1CIP1) induction and as a potential therapeutic target in prostate cancer. Oncogene 2008; 27:3313-28; PMID:18071305; http://dx.doi.org/10.1038/sj.onc.1210986
23. Yu DD, Forman BM. Identification of an agonist ligandfor estrogen-related receptors ERRbetagamma 1. BioorgMedChemLett 2005; 15:1311-3.
24. Zuercher WJ, Gaillard S, Orband-Miller LA, Chao EY, Shearer BG, Jones DG, Miller AB, Collins JL, McDonnell DP, Willson TM. Identification and structureactivity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. J Med Chem 2005; 48:3107-9; PMID:15857113; http://dx.doi.org/10.1021/jm050161j
25. Yu S, Wang X, Ng CF, Chen S, Chan FL. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer. Cancer Res 2007; 67:4904-14; PMID:17510420; http://dx.doi.org/10.1158/0008-5472.CAN-06-3855
26. Wang L, Zuercher WJ, Consler TG, Lambert MH, Miller AB, Orband-Miller LA, McKee DD, Willson TM, Nolte RT. X-ray crystal structures of the estrogenrelated receptor-gamma ligand binding domain in three functional states reveal the molecular basis of small molecule regulation. J Biol Chem 2006; 281:37773-81; PMID:16990259; http://dx.doi.org/10.1074/jbc.M608410200
27. Wang Y, Arvanites AC, Davidow L, Blanchard J, Lam K, Yoo JW, Coy S, Rubin LL, McMahon AP. Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS Chem Biol 2012; 7:1040-8; PMID:22554036; http://dx.doi.org/10.1021/cb300028a
28. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000; 406:1005-9; PMID:10984056; http://dx.doi.org/10.1038/35023008
29. Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina MS, Goldsmith R, Gould SE, Guichert O, Gunzner JL, Halladay J, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009; 19:5576-81; PMID:19716296; http://dx.doi.org/10.1016/j.bmcl.2009.08.049
30. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, Bazett-Jones DP, Allis CD. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997; 106:348-60; PMID:9362543; http://dx.doi.org/10.1007/s004120050256
31. Guo XW, Th'ng JP, Swank RA, Anderson HJ, Tudan C, Bradbury EM, Roberge M. Chromosome condensation induced by fostriecin does not require p34cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation. EMBO J 1995; 14:976-85; PMID:7889943
32. Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol 2007; 27:662-77; PMID:17060456; http://dx.doi.org/10.1128/MCB.00537-06
33. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009; 106:3964-9; PMID:19225112; http://dx.doi.org/10.1073/pnas.0813333106
34. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1-CIP1 expression. Nat Genet 1997; 15:78-82; PMID:8988173; http://dx.doi.org/10.1038/ng0197-78
35. Chan CH, Gao Y, Moten A, Lin HK. Novel ARFp53-independent senescence pathways in cancer repression. J Mol Med (Berl) 2011; 89:857-67; PMID:21594579; http://dx.doi.org/10.1007/s00109-011-0766-y
36. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31:3406-15; PMID:12824337; http://dx.doi.org/10.1093/nar/gkg595
37. Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 2005; 11:6333-41; PMID:16144938; http://dx.doi.org/10.1158/1078-0432.CCR-05-0148
38. Luo KQ, Chang DC. The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. Biochem Biophys Res Commun 2004; 318:303-10; PMID:15110788; http://dx.doi.org/10.1016/j.bbrc.2004.04.027
39. Rudnick SI, Swaminathan J, Sumaroka M, Liebhaber S, Gewirtz AM. Effects of local mRNA structure on posttranscriptional gene silencing. Proc Natl Acad Sci U S A 2008; 105:13787-92; PMID:18784366; http://dx.doi.org/10.1073/pnas.0805781105
40. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011; 8:25-37; PMID:20975744; http://dx.doi.org/10.1038/nrclinonc.2010.174
41. Mahyar-Roemer M, Roemer K. p21 Waf1Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 2001; 20:3387-98; PMID:11423989; http://dx.doi.org/10.1038/sj.onc.1204440
42. Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, Karin M. The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell 2000; 103:897-907; PMID:11136975; http://dx.doi.org/10.1016/S0092-8674(00)00193-8
43. Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, Ozawa T, James CD, Waldman T. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010; 70:3228-38; PMID:20354191; http://dx.doi.org/10.1158/0008-5472.CAN-09-4559
44. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 2007; 104:15472-7; PMID:17875987; http://dx.doi.org/10.1073/pnas.0707351104
45. Boise LH, González-Garc-?a M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608; PMID:8358789; http://dx.doi.org/10.1016/0092-8674(93)90508-N
46. Laitem C, Leprivier G, Choul-Li S, Begue A, Monte D, Larsimont D, Dumont P, Duterque-Coquillaud M, Aumercier M. Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular localization of Ets-1 p51. Oncogene 2009; 28:2087-99; PMID:19377509; http://dx.doi.org/10.1038/onc.2009.72
47. Sierens JE, Scobie GA, Wilson J, Saunders PT. Cloning of oestrogen receptor beta from Old and New World primates: identification of splice variants and functional analysis. J Mol Endocrinol 2004; 32:703-18; PMID:15171710; http://dx.doi.org/10.1677/jme.0.0320703
48. Bonnal S, Vigevani L, Valcárcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 2012; 11:847-59; PMID:23123942; http://dx.doi.org/10.1038/nrd3823
49. Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Clarke R. Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (Faslodex, Fulvestrant). Cancer Res 2004; 64:4030-9; PMID:15173018; http://dx.doi.org/10.1158/0008-5472.CAN-03-3602
50. Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, et al. ERR{gamma} mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res 2008; 68:8908-17; PMID:18974135; http://dx.doi.org/10.1158/0008-5472.CAN-08-2669
51. Buganim Y, Faddah DA, Cheng AW, Itskovich E, Markoulaki S, Ganz K, Klemm SL, van Oudenaarden A, Jaenisch R. Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 2012; 150:1209-22; PMID:22980981; http://dx.doi.org/10.1016/j.cell.2012.08.023